about
I-FABP as biomarker for the early diagnosis of acute mesenteric ischemia and resultant lung injury.Obstructive Sleep Apnea: A Risk Factor for Surgical Site Infection following Colectomy.Persistent Empiric COPD Diagnosis and Treatment After Pulmonary Function Test Showed No Obstruction.Lost in interpretation: should the highest VC value be used to calculate the FEV1/VC ratio?Osteopontin is associated with inflammation and mortality in a mouse model of polymicrobial sepsis.Effects of anesthetic regimes on inflammatory responses in a rat model of acute lung injury.Higher BMI is associated with higher expiratory airflow normalised for lung volume (FEF25-75/FVC) in COPDA health system-based critical care program with a novel tele-ICU: implementation, cost, and structure details.Does Size Matter in ICU Telemedicine?Metabolomics in COPD Acute Respiratory Failure Requiring Noninvasive Positive Pressure Ventilation.Acute cor pulmonale due to pulmonary tumour thrombotic microangiopathy from renal cell carcinoma.Does normal spirometry rule out an obstructive or restrictive ventilatory defect?Chronic Obstructive Pulmonary Disease: Defining the Indefinable.Predictive value of prebronchodilator and postbronchodilator spirometry for COPD features and outcomes.The difference between slow and forced vital capacity increases with increasing body mass index: a paradoxical difference in low and normal body mass indices.Outcomes comparison in patients admitted to low complexity rural and urban intensive care units in the Veterans Health AdministrationFactitious respiratory failure: bound to the ventilator by pressure supportLongitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene StudyICU Telemedicine Reduces Interhospital ICU Transfers in the Veterans Health AdministrationAn automated computerized critical illness severity scoring system derived from APACHE III: modified APACHECombined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease
P50
Q35534226-2740986D-22A7-4632-ACBC-B68D46CB67CFQ38540746-DDA00539-0B23-468D-9432-7E67EC53EE49Q40760855-EDBF10C0-78AE-4484-AFF1-44768E0A3C3BQ41102948-43DE156F-AB46-4A5C-8AFE-58E056D7D580Q41695958-6BB30CD3-FEB3-4070-8A71-4F04C89B1CDEQ41912324-0DD1E4D8-EA26-4EE2-911D-FB937887838BQ42650160-C6DCDF9E-D3CC-4F06-B299-92C1A8AF3D90Q45354347-73AC5AEF-985F-458A-A78D-8240D32202FFQ47222301-04ADF1CF-F185-4F07-B9E4-80C98B781303Q47637919-26223D74-E723-4453-90BB-2B3549791229Q47849217-73938E05-5AEF-4FE1-97BD-A030013D3B35Q48012296-F7D56E2D-6094-4450-A220-A912C82514C3Q48375327-B30C98AB-4C7B-4B5C-AB2B-A93448AB0817Q49521857-C81FA193-229E-462D-8AD8-EC516D91F918Q51690638-B2DB2872-E808-407E-9873-76DF0D161F21Q58588452-739577CD-E166-4341-9F37-39294A6ADE8EQ82264816-78ED30DD-E255-4FC1-A97D-AAAA77EEA004Q89009828-3EAFB3AB-10C8-4A14-A360-3F7AF7FDF564Q89142424-88B22A88-6844-452B-B496-A40C5A7DAF0CQ91648058-E2D7487F-C471-448B-AF39-1006F2F12047Q92601684-04EE3BDB-C5D9-4062-B078-7F917559F47E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Spyridon Fortis
@ast
Spyridon Fortis
@en
Spyridon Fortis
@es
Spyridon Fortis
@nl
type
label
Spyridon Fortis
@ast
Spyridon Fortis
@en
Spyridon Fortis
@es
Spyridon Fortis
@nl
prefLabel
Spyridon Fortis
@ast
Spyridon Fortis
@en
Spyridon Fortis
@es
Spyridon Fortis
@nl
P106
P31
P496
0000-0001-7807-6740